Testosterone therapy: what the evidence actually shows

Testosterone therapy is a treatment for hypogonadism, a clinical diagnosis, not a response to feeling tired or unmotivated. The Endocrine Society’s clinical practice guideline recommends diagnosing hypogonadism only in men who have both symptoms consistent with low testosterone (such as low libido, erectile dysfunction, or loss of body and facial hair) and unequivocally, consistently low morning serum testosterone, confirmed on a repeat measurement rather than a single blood draw.^[3] Testosterone concentrations fluctuate through the day and are highest in the morning, which is why the guideline is specific about both the timing of the test and the need to confirm a low result before treating it as a diagnosis.

That distinction matters because testosterone therapy sits in the same category as another hormone treatment we cover, menopausal hormone therapy: both treat a specific, diagnosable hormonal state under guideline-driven criteria, both carry regimen-specific risks that require individualized decisions, and neither is a blanket wellness intervention for people without the underlying diagnosis.

The most direct evidence on what testosterone therapy does for symptoms comes from the Testosterone Trials, a coordinated set of placebo-controlled trials in older men with confirmed low testosterone that measured several symptom domains at once.^[1] The results were not uniform across domains, which is the central, underreported finding of the whole program.

Sexual function, activity, and desire improved to a moderate degree with testosterone treatment compared with placebo, the most consistent and clearly supported benefit the trials found.^[1]

Physical function, measured mainly through walking ability, showed a modest and inconsistent effect: it reached statistical significance only when data were pooled across trials, not in the dedicated physical-function trial analyzed on its own.^[1] Mood and depressive symptoms improved slightly.^[1]

There was no significant benefit for vitality or fatigue, the domain most closely tied to how testosterone is marketed to the public.^[1]

The gap between the trial results above and how testosterone is often sold matters. A treatment with a moderate, well-supported benefit for sexual function and no demonstrated benefit for vitality or energy is not the same thing as a general anti-aging or energy tonic, even though it is frequently marketed that way to men with normal testosterone levels who simply feel run down.

None of the evidence above applies to men with testosterone levels in the normal range. The Testosterone Trials, the TRAVERSE safety trial discussed next, and the Endocrine Society guideline all describe testosterone therapy for men with confirmed hypogonadism, not a supplement for otherwise healthy aging.

Concerns about testosterone therapy and cardiovascular risk led to a dedicated safety trial, TRAVERSE, a large randomized, placebo-controlled noninferiority trial in middle-aged and older men (45 to 80 years old) with hypogonadism and either existing cardiovascular disease or a high risk of it.^[2]The trial’s primary question was whether testosterone was meaningfully worse than placebo for major adverse cardiac events: cardiovascular death, non-fatal heart attack, or non-fatal stroke.

It was not. Major adverse cardiac events occurred in 7.0% of the testosterone group compared with 7.3% of the placebo group, meeting the trial’s prespecified noninferiority criteria.^[2]

The same trial found higher rates of atrial fibrillation, acute kidney injury, and pulmonary embolism in the testosterone group compared with placebo.^[2] These are secondary findings from a single trial rather than the trial’s primary result, but they are real signals from the most rigorous cardiovascular safety study this treatment has had, and they are part of the honest picture alongside the reassuring headline number.

The Endocrine Society guideline recommends against testosterone therapy in specific situations where the risks are considered to outweigh the benefits, or where the treatment works directly against another goal.^[3] Men who are planning to father a child in the near term are one such group: exogenous testosterone suppresses the body’s own hormonal signal for sperm production, which can reduce fertility while treatment continues.

Most men on testosterone therapy do not experience serious complications, but the safety signals from the trials above point to specific symptoms that warrant prompt medical attention rather than waiting for a routine follow-up.

Outside of these patterns, the picture above holds: this is an effective treatment for a specific, diagnosed condition, and the decision to start, continue, or stop belongs in a conversation with a clinician who knows your health history and is monitoring the relevant blood work.

Testosterone therapy is real medicine for a real, narrowly defined diagnosis: symptoms plus confirmed, repeatedly low morning testosterone. Within that population, the evidence supports a moderate benefit for sexual function, a smaller and less consistent benefit for physical function, and a slight improvement in mood, but not the general vitality or anti-aging effect the treatment is often sold on. The dedicated cardiovascular safety trial is reassuring on major cardiac events but also surfaced higher rates of atrial fibrillation, acute kidney injury, and pulmonary embolism, which is why ongoing monitoring is part of appropriate care rather than an optional extra. See how we grade the strength of evidence across topics in our editorial and evidence standards, and browse the rest of our Hormone & Vitality coverage as it grows.

None of this replaces an individual conversation with a prescribing clinician who knows your symptoms, lab results, and health history. It reflects what the pivotal trials and a major clinical guideline actually show: a genuinely useful treatment for a specific diagnosis, with real trade-offs, not an energy supplement.